The FDA has accepted the Biologics License Application (BLA) for the TLX250-CDx imaging agent (Zircaix®). This investigational PET imaging tool is designed to diagnose and characterize clear cell renal cell carcinoma (ccRCC), the ...
When you partner with Syenza, it’s like a Nuclear Fusion.
Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in
health policy, health economics, systems analysis, public finance, business, and project management.
You’ll also feel our high-impact global and local perspectives with cultural intelligence.